Fucoxanthin exert dose-dependent antifibrotic and anti-inflammatory effects on CCl4-induced liver fibrosis
- 30 June 2023
- journal article
- research article
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 77 (4) , 953-963
Abstract
The lack of an effective non-surgical liver fibrosis treatment is a major problem in hepatology. Fucoxanthin is a marine xanthophyll that exhibits anti-inflammatory, antioxidant, and hepatoprotective properties, thereby indicating its potential effectiveness in the treatment of liver fibrosis. The study aims to investigate the antifibrotic and anti-inflammatory effects of fucoxanthin and its main mechanisms on carbon tetrachloride (CCl4)-induced liver fibrosis in 50 outbred ICR/CD1 mice. 2 μl/g of CCl4 were injected intraperitoneally 2 times a week for 6 weeks. Fucoxanthin (5, 10, 30 mg/kg) was administered via gavage. Liver histopathology was evaluated by Hematoxylin–Eosin (H&E) and Sirius Red staining using the METAVIR scale. The immunohistochemical method was used to determine the number of CD45 and α-smooth muscle actin (α-SMA) positive cells, and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), matrix metalloproteinase-9 (MMP-9), and α-SMA positive areas. Using enzyme immunoassays, procollagen 1 (COL1A1), transforming growth factor-β (TGF-β), and hepatocyte growth factor (HGF) were determined in homogenate, and interleukin-1ß (IL-1ß) and tumor necrosis factor-α (TNF-α) were determined in blood serum. Serum alanine aminotransferase (ALT) and aspartate transaminase (AST) activity, albumin (ALB), and total bilirubin (Tbil) levels are determined by biochemical assays. Fucoxanthin significantly reduced the severity of liver fibrosis, profibrogenic markers, inflammatory infiltration, and pro-inflammatory cytokines. In summary, we confirmed that fucoxanthin has a dose-dependent antifibrotic effect on CCl4-induced liver fibrosis. We found that the anti-inflammatory effect of fucoxanthin is related to the inhibition of IL-1β and TNF-α synthesis, as well as the decrease in the number of leukocytes in the injured liver. Graphical abstractKeywords
This publication has 37 references indexed in Scilit:
- Fucoxanthin Activates Apoptosis via Inhibition of PI3K/Akt/mTOR Pathway and Suppresses Invasion and Migration by Restriction of p38-MMP-2/9 Pathway in Human Glioblastoma CellsNeurochemical Research, 2016
- Fucoxanthin derivatives from Sargassum siliquastrum inhibit matrix metalloproteinases by suppressing NF-κB and MAPKs in human fibrosarcoma cellsALGAE, 2014
- Hepatic inflammation and fibrosis: Functional links and key pathwaysHepatology, 2014
- Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiologyNature Communications, 2013
- Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-κB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophagesEuropean Journal of Pharmacology, 2010
- Blood sample collection in small laboratory animalsJournal of Pharmacology and Pharmacotherapeutics, 2010
- Fucoxanthin supplementation improves plasma and hepatic lipid metabolism and blood glucose concentration in high-fat fed C57BL/6N miceChemico-Biological Interactions, 2010
- Bioavailability and metabolism of fucoxanthin in rats: structural characterization of metabolites by LC-MS (APCI)Molecular and Cellular Biochemistry, 2009
- The distribution and accumulation of fucoxanthin and its metabolites after oral administration in miceBritish Journal of Nutrition, 2009
- Single and repeated oral dose toxicity study of fucoxanthin (FX), a marine carotenoid, in miceThe Journal of Toxicological Sciences, 2009